# OnCo record paper-leap-012-lancet-2025 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-leap-012-lancet-2025/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-leap-012-lancet-2025" ;
  schema:name "LEAP-012: transarterial chemoembolisation with lenvatinib plus pembrolizumab versus placebo for unresectable non-metastatic hepatocellular carcinoma"@en ;
  schema:description "Adding lenvatinib and pembrolizumab to chemoembolisation delayed progression in intermediate-stage liver cancer, the second trial to show that systemic therapy improves on embolisation alone, at the cost of more side effects."@en ;
  schema:url <https://onco.cc/key-papers/paper-leap-012-lancet-2025/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:citation <https://doi.org/10.1016/S0140-6736(24)02575-3>, <https://pubmed.ncbi.nlm.nih.gov/39798578/> ;
  schema:sameAs <https://doi.org/10.1016/S0140-6736(24)02575-3> ;
  schema:datePublished "2025"^^xsd:gYear ;
  schema:author "Kudo M, Ren Z, Guo Y, et al." ;
  onco:cancers <https://onco.cc/cancers/hcc-intermediate/> ;
  onco:drugs <https://onco.cc/drugs/lenvatinib/>, <https://onco.cc/drugs/pembrolizumab/> ;
  onco:trials <https://onco.cc/trials/leap-012/> ;
  onco:journals <https://onco.cc/journals/lancet/> .